Therapy with Trifluridine/Tipiracil and Regorafenib in Patientswith Pre-treated Metastatic Colorectal Cancer –⁠ Experience from the Czech Republic

Czech version

Authors: Peter Grell
Authors‘ workplace: Klinika komplexní onkologické péče, Masarykův onkologický ústav v Brně
Published in: Klin Onkol 2020; 33(3): 234-235
Category: Short Communication
doi: https://doi.org/10.14735/amko2020234

Sources

1. IARC CancerBase No. 11. [online]. Available from: http: //globocan.iarc.fr.

2. Novotvary 2016. [online]. Dostupné z: https: //www.uzis.cz/sites/default/files/knihovna/novotvary2016.pdf.

3. Modest DP, Stintzing S, von Weikersthal LF et al. Impact of subsequent therapies on outcome of the FIRE-3/AIO KRK0306 trial: first-line therapy with FOLFIRI plus cetuximab or bevacizumab in patients with KRAS wild-type tumors in metastatic colorectal cancer. J Clin Oncol 2015; 33 (32): 3718–3726. doi: 10.1200/JCO.2015.61.2887.

4. Grell P, Borilova S, Schwanzer R et al. Factors associated with effectiveness of trifluridine/tipiracil versus regorafenib in patients with pretreated metastatic colorectal cancer (mCRC). J Clin Oncol 2020; 38 (Suppl 4): 137. doi: 10.1200/JCO.2020.38.4_suppl.137.